Aim Bulletin
Microlise acquires K-Safe assets for £0.14m
Fleet software specialist Microlise announced the acquisition of the assets of K-Safe - the parent company behind road safety products Flare and Flare Aware - on Tuesday.
Sabien flags decent first-half growth
Sabien Technology said in an update on Tuesday that in its first half, its cloud-enabled gas boiler energy-saving solution, M2G, demonstrated significant improvements in its key performance indicators.
Kooth launches youth mental health platform in California
Digital mental wellbeing specialist Kooth announced the launch of its digital mental health platform and mobile app in California on Tuesday, under the name ‘Soluna’.
Golden Metal announces new Garfield bedrock discovery
Nevada-focussed mineral explorer Golden Metal Resources announced a new high-grade gold-silver-copper bedrock discovery within its wholly-owned Garfield project on Tuesday, in the Walker Lane Mineral Belt.
IQE appoints new vice president of government affairs
Semiconductor wafer company IQE announced the appointment of Rina Pal-Goetzen as its vice president of government affairs on Tuesday.
MaxCyte flags uptick in total fourth-quarter revenue
Cell engineering company MaxCyte said on Tuesday that total fourth-quarter revenue was expected to be between $15. 5m and $15. 7m.
Mattioli Woods reports positive first-half performance
Wealth and asset management firm Mattioli Woods reported positive first-half performance in an update on Tuesday, despite challenging market conditions.
Seeing Machines takes wraps off next-gen driver monitoring system
Driver monitoring technology specialist Seeing Machines unveiled Guardian Generation 3, the newest iteration of its aftermarket driver monitoring system (DMS), on Tuesday.
Market movements offset quarterly net outflows for Impax
Sustainability-focussed investor Impax said in an update on Tuesday that as of 31 December, its assets under management totalled £39. 1bn, reflecting a 4. 6% increase over the preceding three months.
Faron launches second phase of leukaemia treatment trial
Faron Pharmaceuticals has initiated phase two of the BEXMAB trial, it announced on Tuesday, marking a significant milestone in its cancer treatment development programme.
Strong second half boosts profits at Shoe Zone
Shoe Zone reported a jump in full-year profits on Monday, boosted by strong summer and back to school trading.